BACKGROUND： Extracts of ginkgo biloba leaves （EGB） and its metabolites have been reported to enhance brain function and nerve behavior. It has also been hypothesized that they can protect neurons from oxidative str...BACKGROUND： Extracts of ginkgo biloba leaves （EGB） and its metabolites have been reported to enhance brain function and nerve behavior. It has also been hypothesized that they can protect neurons from oxidative stress. OBJECTIVE： To investigate protective effects of EGB on peroxide （H2O2）-induced oxidative stress damage in PC12 cells. DESIGN： Observational contrast study. SETTING： Department ofPathophysiology, Guangdong Pharmacological College. MATERIALS： EGB was provided by Xi＇an Fujie Biotechnological Development Company; 1640 culture medium, methylthiazolyl tetrazolium （MTT）, trypsin and dimathyl sulfoxide （DMSO） by Sigma Company; PC12 cell strain by Cell Center of Medical College of Zhongshan University; calf serum by Hangzhou Sijiqing Bioengineering Company; lactate dehydrogenase （LDH） kit by Nanjing Jiancheng Bioengineering Research Institute. METHODS： The experiment was carried out in Department of Cell Biology of Guangdong Pharmacological College from June to December 2005. ①Cell culture： PC12 cells were cultured in 1640 medium containing 200 g/L fetal calf serum. The cells were diluted to 1 × 10^7 L^-1 and washed every two days. Those cells were used to experiment until they grew in logarithm on solid wall. ② Grouping and intervention： PC12 cells （1 × 10^8L^-1） were plated in 96-well plates with the density of 200 μ L/hole and divided into three groups： normal control group （routinely adding media）, H2O2 group （treating with media and H2O2 for 20 hours） and EGB group （adding media, 100μmol/L EGB and 100 μmol/L H2O2）. ③ MTT assay： PC12 cells （1 × 10^8L^-1） were plated in 96-well plates and divided into three groups with 8 holes for each group. Under sterile condition, cells were added with 5 g/L MTT （100μL） and cultured for 4 hours. And then, 200 μ L DMSO fluid was added and shaken for 30 minutes until blue crystal products formed were dissolved soundly ④ Experimental evaluation： Absorbance （A） at 630 nm was measured and LDH activity was measured at the same time. MAIN OUTCOME MEASURES： Results of MTT assay and LDH activity. RESULTS： ① Results of MTT assay： A value was lower in the H2O2 group than that in the normal control group （P 〈 0.01）, while A value was higher in the EGB group than that in the H2O2 group （P 〈 0.01）. ② LDH activity： LDH activity was higher in the H2O2 group than that in the normal control group （P 〈 0.01 ）, while LDH activity was lower in the EGB group than that in the H2O2 group （P 〈 0.01）. CONCLUSION： EGB can inhibit H2O2-induced oxidative stress damage in PC12 cells possibly by preventing damage to the cell membrane.展开更多
Subjective cognitive decline (SCD) is defined as the presence of self-reported cognitive complaints with unimpaired performance in neuropsychological cognitive tests. SCD has been identified as a precursor of mild cog...Subjective cognitive decline (SCD) is defined as the presence of self-reported cognitive complaints with unimpaired performance in neuropsychological cognitive tests. SCD has been identified as a precursor of mild cognitive impairment (MCI) and potentially represents the earliest clinical sign of Alzheimer’s disease (AD). Standardized extracts of Ginkgo biloba (GBE) are widely used as a treatment for cognitive impairment. Nonetheless, most of the available review articles focus on the effects of GBE in MCI and dementia but not in SCD and its specific cognitive effects. Thus, this review collects and discusses the available published clinical data for the effects of standardized GBE on the early stages of cognitive decline among an age group where SCD becomes a topic—the middle-aged adults. Randomized clinical trials (RCTs), systematic reviews and meta-analyses of standardized GBEs in cognitive decline subjects were searched using PubMed/MEDLINE, Science direct, Cochrane, and Google Scholar until January 2019. Data from relevant RCT were critically evaluated to determine the potential effects of GBE on SCD. The results showed that the number of available GBE studies on SCD is small. Eight studies were selected in which subjects reported memory impairment, in some cases with concerns (worries), and with an average age at onset SCD of 60 years. Six studies gave a proof of efficacy for GBE for the treatment of SCD in at least one cognitive parameter. One study is inconclusive, however, a post-hoc analysis demonstrates efficacy in preventing AD with intake >4 years. The most common GBE dosage used was 240 mg GBE/day over a minimum period of 8 weeks. Hence, there might be beneficial effects of GBE to prevent, improve or delay SCD in the generation of 50 years or older. However, larger, well-defined RCTs using SCD criteria are necessary to further substantiate this effect in SCD subjects.展开更多
基金Initial Funding for Doctor from Guangdong Science and Technology Bureau, No. 06300709Initial Funding for Doctor from Guangdong Pharmaceutical College, No. 43543096
文摘BACKGROUND： Extracts of ginkgo biloba leaves （EGB） and its metabolites have been reported to enhance brain function and nerve behavior. It has also been hypothesized that they can protect neurons from oxidative stress. OBJECTIVE： To investigate protective effects of EGB on peroxide （H2O2）-induced oxidative stress damage in PC12 cells. DESIGN： Observational contrast study. SETTING： Department ofPathophysiology, Guangdong Pharmacological College. MATERIALS： EGB was provided by Xi＇an Fujie Biotechnological Development Company; 1640 culture medium, methylthiazolyl tetrazolium （MTT）, trypsin and dimathyl sulfoxide （DMSO） by Sigma Company; PC12 cell strain by Cell Center of Medical College of Zhongshan University; calf serum by Hangzhou Sijiqing Bioengineering Company; lactate dehydrogenase （LDH） kit by Nanjing Jiancheng Bioengineering Research Institute. METHODS： The experiment was carried out in Department of Cell Biology of Guangdong Pharmacological College from June to December 2005. ①Cell culture： PC12 cells were cultured in 1640 medium containing 200 g/L fetal calf serum. The cells were diluted to 1 × 10^7 L^-1 and washed every two days. Those cells were used to experiment until they grew in logarithm on solid wall. ② Grouping and intervention： PC12 cells （1 × 10^8L^-1） were plated in 96-well plates with the density of 200 μ L/hole and divided into three groups： normal control group （routinely adding media）, H2O2 group （treating with media and H2O2 for 20 hours） and EGB group （adding media, 100μmol/L EGB and 100 μmol/L H2O2）. ③ MTT assay： PC12 cells （1 × 10^8L^-1） were plated in 96-well plates and divided into three groups with 8 holes for each group. Under sterile condition, cells were added with 5 g/L MTT （100μL） and cultured for 4 hours. And then, 200 μ L DMSO fluid was added and shaken for 30 minutes until blue crystal products formed were dissolved soundly ④ Experimental evaluation： Absorbance （A） at 630 nm was measured and LDH activity was measured at the same time. MAIN OUTCOME MEASURES： Results of MTT assay and LDH activity. RESULTS： ① Results of MTT assay： A value was lower in the H2O2 group than that in the normal control group （P 〈 0.01）, while A value was higher in the EGB group than that in the H2O2 group （P 〈 0.01）. ② LDH activity： LDH activity was higher in the H2O2 group than that in the normal control group （P 〈 0.01 ）, while LDH activity was lower in the EGB group than that in the H2O2 group （P 〈 0.01）. CONCLUSION： EGB can inhibit H2O2-induced oxidative stress damage in PC12 cells possibly by preventing damage to the cell membrane.
文摘Subjective cognitive decline (SCD) is defined as the presence of self-reported cognitive complaints with unimpaired performance in neuropsychological cognitive tests. SCD has been identified as a precursor of mild cognitive impairment (MCI) and potentially represents the earliest clinical sign of Alzheimer’s disease (AD). Standardized extracts of Ginkgo biloba (GBE) are widely used as a treatment for cognitive impairment. Nonetheless, most of the available review articles focus on the effects of GBE in MCI and dementia but not in SCD and its specific cognitive effects. Thus, this review collects and discusses the available published clinical data for the effects of standardized GBE on the early stages of cognitive decline among an age group where SCD becomes a topic—the middle-aged adults. Randomized clinical trials (RCTs), systematic reviews and meta-analyses of standardized GBEs in cognitive decline subjects were searched using PubMed/MEDLINE, Science direct, Cochrane, and Google Scholar until January 2019. Data from relevant RCT were critically evaluated to determine the potential effects of GBE on SCD. The results showed that the number of available GBE studies on SCD is small. Eight studies were selected in which subjects reported memory impairment, in some cases with concerns (worries), and with an average age at onset SCD of 60 years. Six studies gave a proof of efficacy for GBE for the treatment of SCD in at least one cognitive parameter. One study is inconclusive, however, a post-hoc analysis demonstrates efficacy in preventing AD with intake >4 years. The most common GBE dosage used was 240 mg GBE/day over a minimum period of 8 weeks. Hence, there might be beneficial effects of GBE to prevent, improve or delay SCD in the generation of 50 years or older. However, larger, well-defined RCTs using SCD criteria are necessary to further substantiate this effect in SCD subjects.
